|
|
Article: Momenta Placement Raises $130.4M For Heparins Bid.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
With the way apparently clearing for approval of its low-molecular-weight heparin, Momenta Pharmaceuticals Inc. raised about $130.4 million by selling about 4.8 million shares of stock at $27.02 each.
The company's stock (NASDAQ:MNTA) closed Friday at $25.18, down $1.84.
Momenta's stock has enjoyed a steady run-up this summer, starting with a 62 percent jump in mid-June after a judge invalidated the patent held by Paris-based Sanofi-Aventis Group for its drug Lovenox (enoxaparin sodium) - a development that opened the door for Momenta to file an abbreviated new drug application for its version of the blood thinner, ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|